TP53 and B-cell chronic lymphocytic leukemia: Ibrutinib and venetoclax as two oral agents were studied in a phase 2 trial in untreated CLL patients with one or more of the high risk features: chromosome 17p deletion, mutated TP53, chromosome 11q deletion, unmutated IGHV, 65 years or older [31].